get a key
steadybase-$ company KROS
account_id none on file
legal_name Keros Therapeutics, Inc.
ticker KROS
cik 1664710
domain kerostx.com
entry_point_account_id none on file
name Keros Therapeutics Inc.
exchange Nasdaq
sector Health Care
calls 0 filings 39 executives 2 family 0
why_nownone on file
callsnone on file
filings
General and administrative expenses also include professional fees for legal, patent, accounting, information technology, auditing, tax and consulting services, and travel expenses and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.

filing / Aug 3, 2026 / receipt

▪ cost of outside consultants, including their fees and related travel expenses, engaged in research and development functions;

filing / Aug 3, 2026 / receipt

Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as our product candidates.

filing / Aug 3, 2026 / receipt

The increased costs may require us to reduce costs in other areas of our business or increase the prices of our services.

filing / Aug 3, 2026 / receipt

Hybrid work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers and devices outside our premises or network, including working at home, while in transit and in public locations.

filing / Aug 3, 2026 / receipt

General and administrative expenses also include professional fees for legal, patent, accounting, information technology, auditing, tax and consulting services, and travel expenses and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.

filing / May 14, 2026 / receipt

▪ cost of outside consultants, including their fees and related travel expenses, engaged in research and development functions;

filing / May 14, 2026 / receipt

As a result of the 2025 Restructuring, we estimated that we realize average annualized cost savings of approximately $17 million.

filing / May 14, 2026 / receipt

Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as our product candidates.

filing / May 14, 2026 / receipt

On May 29, 2025, we announced the implementation of a corporate restructuring, including a reduction in force of approximately 45% of our then-current employee base across all functions, or the 2025 Restructuring.

filing / May 14, 2026 / receipt

The workforce reduction may be disruptive to our operations and could yield unanticipated consequences, such as attrition beyond planned staff reductions, increased difficulties in our day-to-day operations and reduced employee morale, as well as result in weaknesses in our infrastructure and operations, and may increase the risk that we become unable to comply with legal and regulatory requirements.

filing / May 14, 2026 / receipt

Director, Regulatory Operations | {"ats": "greenhouse", "city": null, "state": null, "job_id": "4733188005", "remote": true, "category": "other", "function": "legal", "location": "Remote", "job_title"

company_statement / Sep 11, 2026 / receipt

executives
Christopher Rovaldi President - receipt
Keith Regnante Chief Financial Officer linkedin receipt
familynone on file
upcoming
2026-11-04 earnings call scheduled ir
changes
2026-07-22 Chief Financial Officer, departed sec_8k
2024-06-17 President, appointed sec_8k
mcp_package_hint
steadybase-$